Verus Capital Partners LLC Sells 11,610 Shares of Scholar Rock Holding Corporation $SRRK

Posted by Geri Gentry on Aug 3rd, 2026

Verus Capital Partners LLC reduced its holdings in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK – Free Report) by 52.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 10,490 shares of the company’s stock after selling 11,610 shares during the quarter. Verus Capital Partners LLC’s holdings in Scholar Rock were worth $516,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. IFP Advisors Inc increased its stake in shares of Scholar Rock by 294.1% during the 4th quarter. IFP Advisors Inc now owns 603 shares of the company’s stock worth $27,000 after purchasing an additional 450 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in Scholar Rock in the fourth quarter worth $30,000. Summit Securities Group LLC bought a new stake in shares of Scholar Rock in the fourth quarter valued at $31,000. EverSource Wealth Advisors LLC lifted its position in shares of Scholar Rock by 151.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock valued at $38,000 after buying an additional 525 shares during the last quarter. Finally, Hilton Head Capital Partners LLC bought a new position in shares of Scholar Rock during the 4th quarter worth $44,000. Institutional investors own 91.08% of the company’s stock.

Scholar Rock Trading Down 0.0%

Scholar Rock stock opened at $47.29 on Monday. The stock has a market cap of $5.67 billion, a P/E ratio of -13.17 and a beta of 0.67. Scholar Rock Holding Corporation has a fifty-two week low of $27.07 and a fifty-two week high of $58.49. The firm’s fifty day moving average price is $50.11 and its 200-day moving average price is $47.72. The company has a debt-to-equity ratio of 0.71, a quick ratio of 8.64 and a current ratio of 8.64.

Scholar Rock (NASDAQ:SRRK – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.01). During the same period in the prior year, the firm posted ($0.67) earnings per share. Equities research analysts forecast that Scholar Rock Holding Corporation will post -3.23 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Scholar Rock in a research note on Thursday, June 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Scholar Rock in a research report on Friday, July 17th. Canaccord Genuity Group assumed coverage on shares of Scholar Rock in a research note on Monday, April 20th. They issued a “buy” rating and a $62.00 target price for the company. Wedbush reissued an “outperform” rating and issued a $58.00 price target on shares of Scholar Rock in a research report on Tuesday, July 21st. Finally, Barclays boosted their price target on shares of Scholar Rock from $53.00 to $55.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Four analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $56.21.

Get Our Latest Stock Report on SRRK

Insiders Place Their Bets

In related news, Director Joshua Reed sold 3,053 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $53.74, for a total value of $164,068.22. Following the sale, the director directly owned 19,518 shares of the company’s stock, valued at $1,048,897.32. This trade represents a 13.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeffrey S. Flier sold 3,053 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $53.88, for a total transaction of $164,495.64. Following the completion of the sale, the director directly owned 27,856 shares in the company, valued at $1,500,881.28. This represents a 9.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 17,149 shares of company stock worth $923,108. 10.30% of the stock is owned by corporate insiders.

About Scholar Rock

(Free Report)

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).